You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Dental Adhesives to Prevent Recurrent Caries
SBC: CuRE Innovations, LLC Topic: NIDCRDESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies
SBC: NEUROENE THERAPEUTICS INC Topic: 106DESCRIPTION provided by applicant Epilepsy is the th most common neurological disorder with in people developing epilepsy the occurrence of more than one unprovoked seizure at some point in their lifetime Unfortunately of all patients have intractable medication resistant epilepsy Thus new anti epileptic drugs AEDs that target alternative mechanisms of action are needed ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Screening the Ribosome for New Target Sites
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
HELical Biodegradable Photochemical(HELP)Stents for AVF Maturation
SBC: Inovasc, LLC Topic: 300ABSTRACT Although arteriovenous fistulae AVFs are the preferred mode of dialysis vascular access over fail to mature in that they do not develop an adequate blood flow or diameter to support hemodialysis This results in a very significant clinical morbidity and economic cost At a pathogenetic level AVF maturation failure is due to a small vessels b bad non laminar hemodynamic pr ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Cancer Imaging and Therapy Platform
SBC: BIOINVISION INC Topic: 102Summary We will create a preclinical quantitative Cancer Imaging and Therapy Platform CITP which will allow one to study cancer biology and optimize pipelines of technologies imaging agents imaging methods targeted nano therapeutics tumor models etc especially for metastatic and invasive cancers Today primary tumor mass es are clinically controlled with surgical drug and radiatio ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Liver Surface Nodularity Score as a New Noninvasive Biomarker for Chronic Viral Hepatitis
SBC: ImageIQ, Inc. Topic: 300DESCRIPTION provided by applicant Chronic viral hepatitis is clinically silent until development of cirrhosis and hepatic decompensation Decompensated cirrhosis is a precursor to liver failure and is associated with increased risk of severe esophageal bleeding significant cardiovascular events and death The gold standard for diagnosing cirrhosis is liver biopsy though problems with the pro ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
OXAID: Oxygenating Hydrogel for Diabetic Wound Care
SBC: O2 RegenTech LLC Topic: 200DESCRIPTION provided by applicant Oxygen plays a significant role in wound healing and maintaining elevated tissue oxygenation levels are an important factor in the dermal healing response Specifically non healing diabetic chronic wounds defined as lasting andgt weeks often show devastatingly low oxygen concentrations as low as mmHg oxygen partial pressure In the USA there are more ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
SBC: ATHERSYS, INC. Topic: NIAAADESCRIPTION provided by applicant This is a resubmission of a Phase I Phase II Fast Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome ARDS ARDS is defined as acute onset hypoxemia bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension A novel and exiting possibility is the use of cells as part of the ther ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health